Why Biogen Stock Was a Winner on Wednesday
Prominent biotech (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by piling into the stock, despite a notable guidance cut. By the end of the trading day, Biogen's shares had gained 6%.
Biogen's total revenue for the first quarter of 2026 was $2.48 billion, up 2% year over year. This was sufficient to top the consensus prognosticator forecast of $2.25 billion.
Image source: Getty Images.
Source Fool.com
Biogen Inc. Stock
€179.04
-0.080%
The stock is one of the favorites of our community with 42 Buy predictions and 1 Sell predictions.
With a target price of 203 € there is a slightly positive potential of 13.38% for Biogen Inc. compared to the current price of 179.04 €.
